Non-steroidal compounds

A compound of Formula I, and/or a pharmaceutically acceptable salt, derivative and/or prodrug thereof,

• wherein:
• A is H, halo, alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl or A together with D may form part of a cyclic group as defined below;
• D is H, halo, alkyl, or D together with A may form part of a cyclic group as defined below;
• E is H, halo, alkyl, or E together with D or with F may form part of a cyclic group as defined below, or, E, if required by considerations of valency, is absent;
• F is H, halo, alkyl, or F together with R10 may form part of a cyclic group as defined below;
• R1 is selected from the group consisting of H, halo, OH, alkoxy, OSO2NH2, OSO2NHalkyl and OSO2N(alkyl)2 or may form part of a cyclic group as defined below;
• R2 is selected from the group consisting of H, halo, OH, alkoxy, OalkylC(O)Oalkyl, OSO2NH2, OSO2NHalkyl and OSO2N(alkyl)2 or may form part of a cyclic group as defined below;
• R3 is selected from the group consisting of H;
• halo, alkyl;
• R4 is selected from the group consisting of H;
• halo, alkyl;
• R5 is selected from the group consisting of H;
• halo, and alkyl;
• R6 is selected from the group consisting of H, halo, alkyl, CO2alkyl, OCF3, or R6 together with R7 may form part of a cyclic group as defined below;
• R7 is selected from the group consisting of H, halo, CO2alkyl, NO2, C1-3alkyl, and CN, or R7 together with R6 may form part of a cyclic group as defined below;
• R8 is selected from the group consisting of H, halo, alkyl, CO2alkyl, and OCF3;
• R9 is selected from the group consisting of H;
• halo, and alkyl;
• X is selected from the group consisting of —O— or N(R10);
• R10 is H or R10 together with F may form part of a cyclic group as defined below;
• Z is absent or is —CH2—;
• A and D may together form a —CH2— or —(CH2)2— group linking the two carbons to which they are respectively attached;
• E and D or E and F may together form a —(CH2)4— or —(CH2)5— group linking the carbon atom to which they are respectively attached;
• F and R10 may together form a ═C— group linking the carbon and nitrogen atoms to which they are respectively attached;
• R1 and R2 may together form a —O—CH2—O— linker linking the carbon atoms to which they are respectively attached;
• R6 and R7 may together form a ═N—O—N═ group linking the two carbon atoms to which they are respectively attached;
• wherein alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl and the cyclic groups formed may be optionally substituted with one or more substituents selected from the group consisting of halo, hydroxy, alkyl, haloalkyl, hydroxyalkyl, aryl, alkylaryl, NO2, NH2, NHalkyl, N(alkyl)2, OCF3, CF3, CN, alkoxy, OSO2NH2, OSO2NHalkyl and OSO2N(alkyl)2, C(O)OH, C(O)Oalkyl, C(O)Ocycloalkyl, C(O)Oaryl, C(O)Oarylalkyl, C(O)Oheterocyclyl, C(O)Oheteroaryl, alkylC(O)Oalkyl, alkylC(O)Ocycloalkyl, alkylC(O)Oaryl, alkylC(O)Oarylalkyl, alkylC(O)Oheterocyclyl, alkylC(O)Oheteroaryl, CONH2, CONH(alkyl), CON(alkyl)2, NHC(O)OH, NHC(O)Oalkyl, NHC(O)Ocycloalkyl, NHC(O)Oaryl, NHC(O)Oarylalkyl, NHC(O)Oheterocyclyl, NHC(O)Oheteroaryl, alkylNHC(O)Oalkyl, alkylNHC(O)Ocycloalkyl, alkylNHC(O)Oaryl, alkylNHC(O)Oarylalkyl, alkylNHC(O)Oheterocyclyl, and alkylNHC(O)Oheteroaryl;
• and
• wherein cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl and the cyclic groups formed may form part of an optionally substituted polycyclic or polyaryl group.